ArticleCancer discovery2020
Immune Surveillance in Clinical Regression of Preinvasive Squamous Cell Lung Cancer.
Open access · greenAbstract read
In one paragraph
Article in Cancer discovery, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 59 papers.
0numbers the graph read from it
0cells of the map it votes in
59citing papers in PubMed
5.1field-weighted citation impact, top 3% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
59 citing papers in PubMed, 93 citations in OpenAlex.
- Article
- Comprehensive molecular characterization of cfDNA as predictive and monitoring biomarkers in advanced gastric cancer receiving immunotherapy.Journal for immunotherapy of cancer · 2026Article
- Attention-based deep learning for analysis of pathology images and gene expression data in lung squamous premalignant lesions.Genome medicine · 2026Article
- Upregulation of an Epithelial miRNA Is Associated with Immune Evasion in Progressive Bronchial Premalignant Lesions.Cancer immunology research · 2026Article
- Real-Time Evolutionary Landscape of the Bronchial Epithelium and Corresponding Dynamic Immune Cell Alterations in Lung Squamous Cell Carcinogenesis.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Article
- Translating premalignant biology to accelerate non-small-cell lung cancer interception.Nature reviews. Cancer · 2025Review
- Lysine-specific demethylase 1 controls key OSCC preneoplasia inducer STAT3 through CDK7 phosphorylation during oncogenic progression and immunosuppression.International journal of oral science · 2025Article
- Predicting the Evolution of Lung Squamous Cell Carcinoma In Situ Using Computational Pathology.Bioengineering (Basel, Switzerland) · 2025Article
- Age-dependent cytokine surge in blood precedes cancer diagnosis.Proceedings of the National Academy of Sciences of the United States of America · 2025Article
- Review
- CCR10: a comprehensive review of its function, phylogeny, role in immune cell trafficking and disease pathogenesis.Frontiers in immunology · 2025Review
- Chromosomal instability as a driver of cancer progression.Nature reviews. Genetics · 2025Review
- Non-small-cell lung cancer.Nature reviews. Disease primers · 2024Review
- Oral Pre-malignancy: An Update on Novel Therapeutic Approaches.Current oncology reports · 2024Review
- Graph Perceiver Network for Lung Tumor and Bronchial Premalignant Lesion Stratification from Histopathology.The American journal of pathology · 2024Article
- Tumor initiation and early tumorigenesis: molecular mechanisms and interventional targets.Signal transduction and targeted therapy · 2024Review
- Cigarette Smoking and E-cigarette Use Induce Shared DNA Methylation Changes Linked to Carcinogenesis.Cancer research · 2024Article
- Smoking-associated gene expression alterations in nasal epithelium reveal immune impairment linked to lung cancer risk.Genome medicine · 2024Article
- Bioactive Materials That Promote the Homing of Endogenous Mesenchymal Stem Cells to Improve Wound Healing.International journal of nanomedicine · 2024Review
Corrections and comments
- Commented on by
Authors and funding
38 authors at 13 institutions in 3 countries.
Adam Pennycuick *Lungs for Living Research Centre, UCL Respiratory, University College London, London, United Kingdom.ORCID https://orcid.org/0000-0001-5836-0250
Vitor H Teixeira *Lungs for Living Research Centre, UCL Respiratory, University College London, London, United Kingdom.
Khalid AbdulJabbar *Centre for Evolution and Cancer, The Institute of Cancer Research, London, United Kingdom.ORCID https://orcid.org/0000-0002-4411-4435
Shan E Ahmed Raza *Centre for Evolution and Cancer, The Institute of Cancer Research, London, United Kingdom.ORCID https://orcid.org/0000-0002-1097-1738
Tom Lund *Cancer Immunology Unit, University College London Cancer Institute, University College London, London, United Kingdom.ORCID https://orcid.org/0000-0001-5400-7230
Ayse U AkarcaDepartment of Cellular Pathology, University College London Hospital, London, United Kingdom.ORCID https://orcid.org/0000-0003-0629-3927
Rachel RosenthalCancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, United Kingdom.
Lukas KalinkeLungs for Living Research Centre, UCL Respiratory, University College London, London, United Kingdom.
Deepak P ChandrasekharanLungs for Living Research Centre, UCL Respiratory, University College London, London, United Kingdom.ORCID https://orcid.org/0000-0002-3427-3926
Christodoulos P PipinikasUniversity College London Cancer Institute, London, United Kingdom.
Henry Lee-SixThe Wellcome Trust Sanger Institute, Hinxton, Cambridgeshire, United Kingdom.
Robert E HyndsLungs for Living Research Centre, UCL Respiratory, University College London, London, United Kingdom.ORCID https://orcid.org/0000-0002-2170-8791
Kate H C GowersLungs for Living Research Centre, UCL Respiratory, University College London, London, United Kingdom.
Jake Y HenryDivision of Molecular Pathology, The Institute of Cancer Research, London, United Kingdom.
Fraser R MillarCancer Research UK Edinburgh Centre, Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, United Kingdom.ORCID https://orcid.org/0000-0002-0740-5436
Yeman B HagosCentre for Evolution and Cancer, The Institute of Cancer Research, London, United Kingdom.ORCID https://orcid.org/0000-0002-0357-6297
Celine DenaisLungs for Living Research Centre, UCL Respiratory, University College London, London, United Kingdom.
Mary FalzonDepartment of Cellular Pathology, University College London Hospital, London, United Kingdom.
David A MooreUCL Manchester Lung Cancer Centre of Excellence, London, United Kingdom.
Sophia AntoniouLungs for Living Research Centre, UCL Respiratory, University College London, London, United Kingdom.
Pascal F DurrenbergerLungs for Living Research Centre, UCL Respiratory, University College London, London, United Kingdom.
Andrew J FurnessCancer Immunology Unit, University College London Cancer Institute, University College London, London, United Kingdom.
Bernadette CarrollLungs for Living Research Centre, UCL Respiratory, University College London, London, United Kingdom.
Claire MarceauxPersonalised Oncology Division, The Walter and Eliza Hall Institute of Medical Research, Melbourne, Australia.ORCID https://orcid.org/0000-0002-9107-8772
Marie-Liesse Asselin-LabatPersonalised Oncology Division, The Walter and Eliza Hall Institute of Medical Research, Melbourne, Australia.ORCID https://orcid.org/0000-0001-7082-6076
William LarsonKnight Cancer Institute, Department of Cell, Developmental and Cancer Biology, Oregon Health & Science University, Portland, Oregon.
Courtney BettsKnight Cancer Institute, Department of Cell, Developmental and Cancer Biology, Oregon Health & Science University, Portland, Oregon.
Lisa M CoussensKnight Cancer Institute, Department of Cell, Developmental and Cancer Biology, Oregon Health & Science University, Portland, Oregon.
Ricky M ThakrarLungs for Living Research Centre, UCL Respiratory, University College London, London, United Kingdom.
Jeremy GeorgeLungs for Living Research Centre, UCL Respiratory, University College London, London, United Kingdom.
Charles SwantonUCL Manchester Lung Cancer Centre of Excellence, London, United Kingdom.
Christina ThirlwellUniversity College London Cancer Institute, London, United Kingdom.
Peter J CampbellThe Wellcome Trust Sanger Institute, Hinxton, Cambridgeshire, United Kingdom.
Teresa MarafiotiDepartment of Cellular Pathology, University College London Hospital, London, United Kingdom.ORCID https://orcid.org/0000-0003-1223-6275
Yinyin YuanCentre for Evolution and Cancer, The Institute of Cancer Research, London, United Kingdom.
Sergio A QuezadaCancer Immunology Unit, University College London Cancer Institute, University College London, London, United Kingdom.
Nicholas McGranahanUniversity College London Cancer Institute, London, United Kingdom. s.janes@ucl.ac.uk nicholas.mcgranahan.10@ucl.ac.uk.
Sam M JanesLungs for Living Research Centre, UCL Respiratory, University College London, London, United Kingdom. s.janes@ucl.ac.uk nicholas.mcgranahan.10@ucl.ac.uk.ORCID https://orcid.org/0000-0002-6634-5939
Living Streets · GBInstitute of Cancer Research · GBOregon Health & Science University · USUniversity College Hospital · GBThe Francis Crick Institute · GBCRUK Lung Cancer Centre of Excellence · GBWellcome Sanger Institute · GBCancer Research UK · GBEdinburgh Cancer Research · GBLondon Cancer · GBRoyal Marsden NHS Foundation Trust · GBUniversity of Exeter · GBWalter and Eliza Hall Institute of Medical Research · AU
Funding
Omic and Multidimensional Spatial Atlas of Metastatic Breast CancerU2CCA233280 · NCI · OREGON HEALTH & SCIENCE UNIVERSITY · PI GOECKS, JEREMY · 2018 to 2023
$9.7MThe Role of the Microbiome in Cancer Suppression and Susceptibility Across SpeciesU54CA217376 · NCI · ARIZONA STATE UNIVERSITY-TEMPE CAMPUS · PI MALEY, CARLO · 2018 to 2022
$8.6MTherapeutic Targeting of Macrophage PI3Kgamma in HNSCCR01CA226909 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Kathryn Ann Gold, Judith A VARNER · 2018 to 2026
$3.9MComparative analysis between patient-derived models of pancreatic ductal adenocarcinomas and matched tumor specimensU01CA224012 · NCI · OREGON HEALTH & SCIENCE UNIVERSITY · PI BRODY, JONATHAN, COUSSENS, LISA M. · 2019 to 2023
$2.9M(PQC3) Genomic Diversity and Microenvironment as Drivers of Metastasis in DCISR01CA185138 · NCI · DUKE UNIVERSITY · PI HWANG, E.SHELLEY, MALEY, CARLO · 2014 to 2017
$2.0MIn Situ characterization and manipulation of tumor immune cell metabolomics using implantable microdevicesR01CA223150 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI JONAS, OLIVER · 2018 to 2022
$1.9MMechanisms of metabolic dysfunction in the offspring of maternal obesity: role of inflammationR21HD099367 · NICHD · OREGON HEALTH & SCIENCE UNIVERSITY · PI MALOYAN, ALINA · 2019 to 2020
$411kCancer Research UK 20764Cancer Research UK 22246Cancer Research UK 24956Cancer Research UK A11790Cancer Research UK FC001169European Research Council 835297NCI NIH HHS R01 CA185138NCI NIH HHS R01 CA223150NCI NIH HHS R01 CA226909NCI NIH HHS U01 CA224012NCI NIH HHS U2C CA233280NCI NIH HHS U54 CA217376NICHD NIH HHS R21 HD099367Wellcome Trust 091730Wellcome Trust 209199Wellcome Trust 209199/Z/17/ZWellcome Trust 211179/Z/18/Z
Abstract
Before squamous cell lung cancer develops, precancerous lesions can be found in the airways. From longitudinal monitoring, we know that only half of such lesions become cancer, whereas a third spontaneously regress. Although recent studies have described the presence of an active immune response in high-grade lesions, the mechanisms underpinning clinical regression of precancerous lesions remain unknown. Here, we show that host immune surveillance is strongly implicated in lesion regression. Using bronchoscopic biopsies from human subjects, we find that regressive carcinoma
Indexed as
Carcinoma, Squamous CellHumansImmunologic SurveillanceLung Neoplasms
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.